Key clinical point: The oncogenic role of TRIM31 may provide therapeutic targets.
Major finding: The oncogenic role of TRIM31 in AML was mediated by the Wnt/beta-catenin pathway.
Study details: TRIM31 was assessed in 34 AML patients and 34 healthy volunteers using qRT-PCR.
Disclosures: The study was supported by the National Science Foundation of China and other agencies. No conflicts of interest statement was given.
Xiao Y et al. Biosci Rep. 2020;doi.org/10.1042/BSR20194334. https://doi.org/10.1042/BSR20194334